These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Anti-tumor activities of four chelating agents against human neuroblastoma cells.
    Author: Shen L, Zhao HY, Du J, Wang F.
    Journal: In Vivo; 2005; 19(1):233-6. PubMed ID: 15796180.
    Abstract:
    BACKGROUND: Iron deprivation may be a therapeutic strategy for cancer. It can be achieved by using iron chelators. In this investigation, anti-neuroblastoma activities of a novel ferric chelator 2LL together with DFO, EDTA and DTPA were evaluated. MATERIALS AND METHODS: SH-Sy5y cells were cultured at 37 degrees C in 5% CO2/95% air in DMEM containing 10% fetal bovine serum. The cells were seeded in 96-well microtiter plates overnight. Then, chelating agents were added into the wells. After 48-hour incubation, viabilities were measured using the MTT method. RESULTS: DTPA had an IC50 value between 60-100 microM; DFO produced about 40% inhibiting effect at 150 microM; 2LL and EDTA displayed about 10% inhibiting effect at high concentrations. CONCLUSION: For SH-Sy5y cells, DTPA showed the strongest inhibiting effect, DFO displayed a moderate inhibiting effect, while 2LL and EDTA produced minor inhibition. To develop iron chelators as powerful anti-cancer agents is still a challenging task.
    [Abstract] [Full Text] [Related] [New Search]